Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Quarterly results Appointed COO Notes underwriting agrmnt
|
Vicarious Surgical Inc. (RBOT)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/04/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data
Docs:
|
"$45,000,000 OF SHARES OF",
"OPINION OF MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C",
"Vicarious Surgical Announces Launch of Proposed Public Offering WALTHAM, Mass, August 2, 2023 – Vicarious Surgical Inc. , a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that it has commenced an underwritten public offering of $45.0 million of shares of its Class A common stock . All of the shares of Common Stock are being offered by Vicarious Surgical. In addition, the Company has granted the underwriters a 30-day option to purchase up to $6.75 million of additional shares of its Common Stock. Morgan Stanley & Co. LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. The proposed offering is subject to market and other conditions, and there...",
"Vicarious Surgical Announces Pricing of Public Offering WALTHAM, Mass, August 2, 2023 – Vicarious Surgical Inc. , a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced the pricing of its underwritten public offering of 45,000,000 shares of its Class A common stock at a price to the public of $1.00 per share. In addition, Vicarious Surgical has granted the underwriters a 30-day option to purchase up to an additional 6,750,000 shares of its Common Stock. Before deducting the underwriting discounts and commissions and estimated offering expenses, the Company expects to receive total gross proceeds of approximately $45.0 million, assuming no exercise of the underwriters’ option to purcha..." |
|
07/27/2023 |
8-K
| Investor presentation |
07/27/2023 |
8-K
| Quarterly results |
06/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
05/18/2023 |
8-K
| Appointed COO |
05/08/2023 |
8-K
| Quarterly results |
01/23/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
11/07/2022 |
8-K
| Quarterly results |
10/20/2022 |
8-K
| Quarterly results |
10/13/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
08/08/2022 |
8-K
| Quarterly results |
06/03/2022 |
8-K
| Quarterly results |
05/09/2022 |
8-K
| Quarterly results |
03/08/2022 |
8-K
| Quarterly results |
03/03/2022 |
8-K
| Quarterly results |
11/08/2021 |
8-K
| Quarterly results |
10/20/2021 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte... |
09/23/2021 |
8-K
| Quarterly results |
09/15/2021 |
8-K
| Quarterly results |
09/14/2021 |
8-K
| Quarterly results |
09/10/2021 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat... |
09/07/2021 |
8-K
| Quarterly results |
08/24/2021 |
8-K
| Quarterly results |
05/21/2021 |
8-K
| Quarterly results |
04/15/2021 |
8-K
| Quarterly results |
09/01/2020 |
8-K
| Other Events, Financial Statements and Exhibits |
07/30/2020 |
8-K
| Quarterly results |
07/23/2020 |
8-K
| Quarterly results |
07/17/2020 |
8-K
| Quarterly results |
|
|